Viridian Therapeutics, Inc. VRDN Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $176.35M+51.7% | $212.38M+113% | $169.65M-15.3% | $117.32M+9.0% | $116.22M+26.8% | ||
| $585.84M+12.6% | $662.27M+7.2% | $321.25M-41.9% | $446.03M-3.8% | $520.42M-0.2% | ||
| $784.74M+19.4% | $894.23M+21.1% | $571.91M-25.5% | $578.75M-0.5% | $657.24M+4.9% | ||
| $1.13M-2.8% | $1.23M-0.6% | $1.13M-12.8% | $1.09M-27.9% | $1.16M-23.9% | ||
| $789.02M+19.4% | $899.42M+21.1% | $577.14M-25.2% | $582.32M-0.6% | $660.98M+4.9% | ||
| $13.31M+243% | $8.68M+305% | $10.06M+58.8% | $8.52M+171% | $3.89M+45.2% | ||
| $274K-4.9% | $367K+27.4% | $372K+29.2% | $288K0.0% | $288K0.0% | ||
| $51.81M+53.6% | $70.7M+47.7% | $50.7M+22.6% | $52.59M+43.0% | $33.73M+29.1% | ||
| $36.09M+74.5% | $34.24M— | $20.89M+1.8% | $12.35M-29.4% | $20.69M+1.8% | ||
| $12.5M-77.9% | $20.03M-71.7% | $74.17M+15.2% | $67.16M+19.2% | $56.51M+18.1% | ||
| 200M0.0% | 200M+24,591% | 200M0.0% | 200M0.0% | 200M0.0% | ||
| -$1.44B-33.3% | -$1.34B-34.4% | -$1.22B-33.0% | -$1.18B-41.0% | -$1.08B-39.8% | ||
| $636.01M+5.2% | $722.17M+7.5% | $502.97M-28.9% | $515.17M-2.7% | $604.47M+3.8% | ||
| $789.02M+19.4% | $899.42M+21.1% | $577.14M-25.2% | $582.32M-0.6% | $660.98M+4.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Viridian Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 15.15 — current assets exceed current liabilities.
- Where does Viridian Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.